CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil.

Abstract

The adenosine A2 receptor antagonist CGS 15943 (0.1 mg/kg, i.p.) was tested for cerebroprotective activity in a gerbil stroke model. CGS 15943 markedly reduced stroke injury assessed by locomotor activity monitoring and by histopathological measurement of hippocampal CA1 pyramidal cell injury. It is proposed that a previously demonstrated reduction in the ischemia/reperfusion-evoked release of excitotoxic amino acids following CGS 15943 administration could account for its cerebroprotective actions.

• Authors: Y Gao, J W Phillis
• Journal: Life sciences (Life Sci) Vol. 55 Issue 3 Pg. PL61-5 ( 1994) ISSN: 0024-3205 [Print] Netherlands
• PMID: 8007757 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Purinergic P1 Receptor Antagonists
• Quinazolines
• Triazoles
• 9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine

Topics

• Animals
• Brain Ischemia (drug therapy, pathology)
• Gerbillinae
• Male
• Motor Activity (drug effects)
• Purinergic P1 Receptor Antagonists
• Pyramidal Cells (drug effects, pathology)
• Quinazolines (pharmacology)
• Triazoles (pharmacology)